I-Mab (NASDAQ: IMAB)
$1.79
(-0.6%)
-$0.01
Price as of April 16, 2024, 4:00 p.m. ET
I-Mab Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
I-Mab Company Info
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Pudong, China.
Valuation
Earnings Transcripts
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.